Cherie-Ann Nathan, MD, FACS will deliver the Third Annual Spector Lecture on Wednesday, March 13, 2019. Dr. Nathan currently serves as Jack W. Pou Endowed Professor & Chairman for the Department of Otolaryngology-Head & Neck Surgery, LSU Health – Shreveport and Director of Head and Neck Surgical Oncology for Feist-Weiller Cancer Center. She is a nationally recognized physician-scientist with clinical interests in head and neck surgical oncology and molecular markers in head and neck cancer. Her research has been funded by the National Cancer Institute since 2000 and she is recognized for her work on the molecular analysis of surgical margins.
The annual Spector Lectureship will be held at 7:00AM in the Ogura Learning Center, Room 9917 on the 9th Floor of McMillan Hospital. All are invited to attend.
From the LSU Health website:
Cherie-Ann Nathan, MD, FACS, is the Jack Pou Endowed Professor and Chairman of the Department of Otolaryngology/Head and Neck Surgery at LSU-Health in Shreveport. She is also Director of Head and Neck Oncologic Surgery and Research at the Feist-Weiller Cancer Center. She completed her Otolaryngology/Head and Neck Surgery residency and head and neck fellowship in 1995 at University of California, San Diego. She was a post-doctoral fellow at Johns Hopkins where she started her research career. Following her fellowship, she began her academic career at LSU-Shreveport.
Her passion to improve outcomes for patients with head and neck cancer was the reason she moved from Mumbai India, where she went to medical school. She is a Surgeon-Scientist that maintains a busy practice treating head and neck cancer, thyroid, parathyroid, and salivary gland tumors and she leads an active research team. The National Cancer Institute has funded her translational research since 2000 and her focus is on targeted therapy for head and neck patients. She is recognized nationally and internationally for her seminal work on molecular analysis of surgical margins. She has pioneered multi-institutional clinical trials using mTOR inhibitors in HNSCC patients with both Wyeth and Novartis. She has also received NIH funding for chemoprevention of cancer with curcumin and has a patent for a curcumin chewing gum. Her new RO1 on Targeting the FGFR-2 pathway for cutaneous SCC holds potential for transplant patients with aggressive cSCC. She has published extensively, has over 180 publications in peer-reviewed journals, and has authored multiple textbooks and encyclopedia chapters.
Dr. Nathan is currently the President-Elect of the American Head and Neck Society and President Elect of Association of Academic Depts. of Otolaryngology/Head and Neck Surgery. She also serves on many National committees some of which include the NCI Steering committee, the American Cancer Society-CDC HPV Steering Committee, Executive board of directors for the Head and Neck Cancer Alliance, Council Member for the Society of University Otolaryngology, and the Larynx Preservation Guideline Panel. She is currently co-President of the ASTRO-ASCO Multidisciplinary meeting. She has served on the Nominating committee for the American Academy of Otolaryngology-HNS Program and is the Head & Neck CORE grants research leader. She is also Associate editor for Laryngoscope Investigative Otolaryngology. At the local level she is active, having been on the board of directors for Shreveport Medical Society, Disaster Reform committee and the Science Museum.
The Shreveport-Bossier Commerce Department awarded her the Athena Award for community service and she received the Leonard Tow Humanism award from the Arnold Gold Foundation. The Board of Regents in Louisiana established the Cherie-Ann Nathan Endowed Professorship in Otolaryngology/Head and Neck Surgery initiated by grateful patients to honor her dedication and expertise.